Research programme: nitric oxide donor cancer therapeutics - BNOAT OncologyAlternative Names: Nitrosylcobalamin; NO-Cbl
Latest Information Update: 20 Jul 2016
At a glance
- Originator Nonindustrial source
- Developer BNOAT Oncology
- Class Vitamin B12 analogues
- Mechanism of Action Apoptosis stimulants; Nitric oxide donors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours